APL-2

Phase 3Completed

0 views this week 0 watching💤 Quiet

Interest: 34/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Paroxysmal Nocturnal Hemoglobinuria

Conditions

Paroxysmal Nocturnal Hemoglobinuria

Trial Timeline

Aug 27, 2019 → Jun 23, 2021

NCT ID

NCT04085601

About APL-2

APL-2 is a phase 3 stage product being developed by Apellis Pharmaceuticals for Paroxysmal Nocturnal Hemoglobinuria. The current trial status is completed. This product is registered under clinical trial identifier NCT04085601. Target conditions include Paroxysmal Nocturnal Hemoglobinuria.

What happened to similar drugs?

0 of 20 similar drugs in Paroxysmal Nocturnal Hemoglobinuria were approved

Approved (0) Terminated (4) Active (16)

🔄Crovalimab + EculizumabChugai PharmaceuticalPhase 3

🔄EculizumabAstraZenecaPhase 3

🔄DanicopanAstraZenecaPhase 3

🔄Iptacopan (LNP023)NovartisPhase 3

🔄IptacopanNovartisPhase 3

🔄LNP023 + Eculizumab + RavulizumabNovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04085601	Phase 3	Completed	Aug 27, 2019	Jun 23, 2021	Paroxysmal Nocturnal Hemoglobinuria
NCT03453619	Phase 2	Completed	Feb 26, 2018	Aug 26, 2023	IgA Nephropathy
NCT03226678	Phase 2	Completed	Aug 31, 2017	Sep 12, 2022	Warm Autoimmune Hemolytic Anemia

Competing Products

20 competing products in Paroxysmal Nocturnal Hemoglobinuria

See all competitors

Product	Company	Stage	Hype Score
Crovalimab + Eculizumab	Chugai Pharmaceutical	Phase 3	44
Crovalimab + Placebo	Chugai Pharmaceutical	Phase 1/2	36
Crovalimab + Eculizumab	Chugai Pharmaceutical	Phase 3	44
Ravulizumab	AstraZeneca	Pre-clinical	30
Eculizumab	AstraZeneca	Phase 3	40
Danicopan	AstraZeneca	Phase 3	47
LNP023	Novartis	Pre-clinical	33
Iptacopan (LNP023)	Novartis	Phase 3	40
iptacopan	Novartis	Phase 2	35
LNP023	Novartis	Phase 2	35
Iptacopan	Novartis	Pre-clinical	30
Iptacopan	Novartis	Phase 3	40
LNP023 + Eculizumab + Ravulizumab	Novartis	Phase 3	40
LNP023	Novartis	Phase 3	47
LFG316 + LNP023	Novartis	Phase 2	35
Iptacopan	Novartis	Phase 3	44
Crovalimab	Roche	Phase 3	44
ABP 959 + Eculizumab	Amgen	Phase 3	40
Pegcetacoplan	Swedish Orphan Biovitrum	Pre-clinical	33
BMS-919373 + Placebo (Matching with BMS-919373)	Bristol Myers Squibb	Phase 2	27